Freddie Mac is guaranteeing three senior principal and interest classes and one interest only class of securities issued by the FRESB 2021-SB83 Mortgage Trust. SB83 includes one class (Class A10H) of senior bonds backed in part by hybrid loans indexed to SOFR during their floating-rate period. Freddie Mac is also acting as mortgage loan seller and master servicer to the trust. In addition to the four classes of securities guaranteed by Freddie Mac, the trust will issue certificates consisting of Class B and Class R Certificates, which will not be guaranteed by Freddie Mac and will be sold to private investors.
(2)
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $193.5 million. In addition, KalVista has granted the underwriters a 30-day option to purchase up to an additional 806,250 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by KalVista. The offering is expected to close on or about February 16, 2021, subject to the satisfaction of customary closing conditions.
11.02.2021 - KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the . Seite 1
Thayer Ventures Acquisition Corporation Announces the Separate Trading of its Class A Common Stock and Redeemable Warrants Commencing February 9, 2021 saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vor Biopharma, has announced the pricing of its initial public offering (IPO) of 9,828,017 shares of common stock at a public offering price of $18.00 per share resulting in gross proceeds to Vor of approximately $176.9 million, before underwriting discounts and commissions and offering expenses to be paid by Vor. The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol “VOR” on Friday, February 5, 2021. The offering is expected to close on Tuesday, February 9, 2021,